Publications by authors named "D Petrylak"
Article Synopsis
- The IMvigor210 trial assessed the long-term efficacy and safety of atezolizumab, an anti-PD-L1 therapy, in patients with advanced metastatic urothelial carcinoma (UC), showing manageable toxicity.
- The trial involved two cohorts: untreated UC patients ineligible for cisplatin-based chemotherapy and those previously treated with platinum-based chemotherapy, with a median follow-up of up to 96.4 months.
- Results indicated objective response rates of 23.5% in untreated patients and 16.5% in previously treated patients, with median overall survival of 16.3 months and 7.9 months, respectively, along with a notable percentage of patients experiencing grade 3/4 adverse events. *
Purpose: This multicenter phase Ib study investigated trastuzumab deruxtecan (T-DXd) plus nivolumab in patients with HER2-expressing metastatic breast cancer (mBC) and metastatic urothelial cancer (mUC).
Patients And Methods: Part 1 determined the recommended dose for expansion of T-DXd plus nivolumab. Part 2 evaluated efficacy and safety; the primary endpoint was confirmed objective response rate by independent central review.
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown.
Methods: In this phase 3 trial, we randomly assigned patients, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year or to undergo observation.
Purpose: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Here, we report results from Cohort 2 of TROPHY-U-01 trial, evaluating the efficacy and safety of SG in patients with mUC.
Methods: TROPHY-U-01 (ClinicalTrials.